A securities fraud investigation has been launched into PROCEPT BioRobotics (NASDAQ: PRCT) following the company's February 25, 2026 earnings report, which disclosed larger-than-expected adjusted EBITDA losses and a significant downward revision of full-year 2026 revenue guidance from $410-$430 million to $390-$410 million. The announcement triggered a 15.12% stock price decline ($4.21 per share) on February 26, 2026.

The Law Offices of Frank R. Cruz announced an investigation into PROCEPT BioRobotics Corporation for possible violations of federal securities laws. The investigation follows the company's February 25, 2026 earnings report, which disclosed larger-than-expected adjusted EBITDA losses and a significant cut to full-year 2026 revenue guidance from $410-$430 million to $390-$410 million. The stock fell $4.21 per share (15.12%) to $23.63 on February 26, 2026.

The Schall Law Firm is investigating PROCEPT BioRobotics Corporation for potential securities law violations. The company reported Q4 2025 results on February 25, 2026, with quarterly revenue significantly below analyst expectations and substantially reduced full-year guidance. The company attributed underperformance to realignment disruptions and elimination of bulk-purchase discounts, resulting in a 15.1% stock price decline.

Pomerantz LLP is investigating potential securities fraud claims against PROCEPT BioRobotics Corporation after the company reported Q4 2025 revenue that missed analyst expectations and significantly cut its 2026 revenue guidance from $410-$430 million to $390-$410 million, citing commercial organization disruptions and elimination of bulk-purchasing discounts. The stock fell 15.12% on the news.

Procept BioRobotics reported strong Q2 2025 financial results with 48.3% revenue growth, reaching $79.2 million, driven by increased U.S. and international sales of robotic surgical systems for BPH treatment.

PROCEPT BioRobotics announced leadership transition with Dr. Reza Zadno retiring and Larry L. Wood becoming the new president and CEO effective September 2, 2025. The company also pre-announced Q2 2025 revenue of $79.2 million, representing 48% annual growth.

PROCEPT BioRobotics announced a new Category I CPT code for Aquablation therapy, effective January 1, 2026, with Medicare payment rates comparable to traditional TURP procedures, signaling broader recognition and potential adoption of their BPH treatment technology.

Several mid-cap stocks, including Globalstar, V.F. Corp, and Madrigal Pharmaceuticals, were among the top gainers last week. The companies reported positive financial results and business updates, leading to the stock price increases.

PROCEPT BioRobotics announced FDA clearance of its next-generation HYDROS Robotic System, which features AI-powered treatment planning, advanced image guidance, and robotic resection to deliver improved efficiency, enhanced user experience, and better clinical outcomes for Aquablation therapy.

SAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association (“AMA”) has established a new Current Procedural Terminology (“CPT”) Category I code for transurethral waterjet resection of prostate tissue (“Aquablation therapy”) to treat benign prostatic hyperplasia (“BPH”).

SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time.

SAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20 a.m. Eastern Time. Additionally, members of management will present at the upcoming 44th Annual William Blair Growth Stock Conference in Chicago. Management is scheduled to present on Tuesday, June 4 at 5:00 p.m. Eastern Time.